{"url_path":"/sec/ctso/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1175151/0001104659-26-060270-index.html","accession_number":"0001104659-26-060270","cik":"0001175151","ticker":"CTSO","issuer_name":"Cytosorbents Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1175151/0001104659-26-060270-index.html","primary_entity_key":"0001175151","primary_entity_name":"Cytosorbents Corp"},"word_count":843,"has_tables":true,"body_markdown":"CYTOSORBENTS CORPORATION_March 31, 2026\n\n0001175151--12-312026Q1falsehttp://fasb.org/us-gaap/2025#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMemberhttp://fasb.org/us-gaap/2025#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMemberhttp://fasb.org/us-gaap/2025#PrimeRateMemberP3MP6Y0001175151srt:MinimumMemberctso:SeriesBRightWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2025-01-100001175151srt:MinimumMemberctso:SeriesaRightWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2025-01-100001175151srt:MaximumMemberctso:SeriesBRightWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2025-01-100001175151srt:MaximumMemberctso:SeriesaRightWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2025-01-100001175151ctso:SeriesBRightWarrantsMemberus-gaap:MeasurementInputSharePriceMember2025-01-100001175151ctso:SeriesBRightWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-01-100001175151ctso:SeriesBRightWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-01-100001175151ctso:SeriesBRightWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2025-01-100001175151ctso:SeriesaRightWarrantsMemberus-gaap:MeasurementInputSharePriceMember2025-01-100001175151ctso:SeriesaRightWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-01-100001175151ctso:SeriesaRightWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-01-100001175151ctso:SeriesaRightWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2025-01-100001175151ctso:WarrantTwoMemberctso:LoanAndSecurityAgreementMember2026-03-310001175151ctso:WarrantOneMemberctso:LoanAndSecurityAgreementMember2026-03-310001175151us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001175151us-gaap:CommonStockMember2026-01-012026-03-310001175151us-gaap:RetainedEarningsMember2026-03-310001175151us-gaap:AdditionalPaidInCapitalMember2026-03-310001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001175151us-gaap:RetainedEarningsMember2025-12-310001175151us-gaap:AdditionalPaidInCapitalMember2025-12-310001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001175151us-gaap:RetainedEarningsMember2025-03-310001175151us-gaap:AdditionalPaidInCapitalMember2025-03-310001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001175151us-gaap:RetainedEarningsMember2024-12-310001175151us-gaap:AdditionalPaidInCapitalMember2024-12-310001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001175151us-gaap:CommonStockMember2026-03-310001175151us-gaap:CommonStockMember2025-12-310001175151us-gaap:CommonStockMember2025-03-310001175151us-gaap:CommonStockMember2024-12-310001175151srt:MinimumMemberus-gaap:EmployeeStockOptionMember2026-03-310001175151srt:MaximumMemberus-gaap:EmployeeStockOptionMember2026-03-310001175151ctso:OtherRsuMember2026-03-310001175151ctso:ControlBasedRsusMember2026-03-310001175151ctso:OtherRsuMember2025-12-310001175151ctso:ControlBasedRsusMember2025-12-310001175151ctso:OtherRsuMember2026-01-012026-03-310001175151ctso:ControlBasedRsusMember2026-01-012026-03-310001175151us-gaap:SellingGeneralAndAdministrativeExpensesMember2026-01-012026-03-310001175151us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001175151us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001175151us-gaap:CostOfSalesMember2026-01-012026-03-310001175151us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-03-310001175151us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001175151us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001175151us-gaap:CostOfSalesMember2025-01-012025-03-310001175151ctso:AllOtherCountriesMemberus-gaap:SalesChannelThroughIntermediaryMember2026-01-012026-03-310001175151ctso:AllOtherCountriesMemberus-gaap:SalesChannelDirectlyToConsumerMember2026-01-012026-03-310001175151country:USus-gaap:SalesChannelDirectlyToConsumerMember2026-01-012026-03-310001175151country:DEus-gaap:SalesChannelDirectlyToConsumerMember2026-01-012026-03-310001175151us-gaap:SalesChannelThroughIntermediaryMember2026-01-012026-03-310001175151us-gaap:SalesChannelDirectlyToConsumerMember2026-01-012026-03-310001175151ctso:AllOtherCountriesMember2026-01-012026-03-310001175151country:US2026-01-012026-03-310001175151country:DE2026-01-012026-03-310001175151ctso:AllOtherCountriesMemberus-gaap:SalesChannelThroughIntermediaryMember2025-01-012025-03-310001175151ctso:AllOtherCountriesMemberus-gaap:SalesChannelDirectlyToConsumerMember2025-01-012025-03-310001175151country:USus-gaap:SalesChannelDirectlyToConsumerMember2025-01-012025-03-310001175151country:DEus-gaap:SalesChannelDirectlyToConsumerMember2025-01-012025-03-310001175151us-gaap:SalesChannelThroughIntermediaryMember2025-01-012025-03-310001175151us-gaap:SalesChannelDirectlyToConsumerMember2025-01-012025-03-310001175151ctso:AllOtherCountriesMember2025-01-012025-03-310001175151country:US2025-01-012025-03-310001175151country:DE2025-01-012025-03-3100011751512025-10-012025-12-310001175151ctso:LoanAndSecurityAgreementMember2025-01-1000011751512025-01-100001175151srt:MinimumMemberus-gaap:ComputerEquipmentMember2026-03-310001175151srt:MaximumMemberus-gaap:ComputerEquipmentMember2026-03-310001175151srt:MinimumMemberus-gaap:ComputerEquipmentMember2025-12-310001175151srt:MaximumMemberus-gaap:ComputerEquipmentMember2025-12-310001175151us-gaap:LeaseholdImprovementsMember2026-03-310001175151us-gaap:FurnitureAndFixturesMember2026-03-310001175151us-gaap:ComputerEquipmentMember2026-03-310001175151us-gaap:LeaseholdImprovementsMember2025-12-310001175151us-gaap:FurnitureAndFixturesMember2025-12-310001175151us-gaap:ComputerEquipmentMember2025-12-3100011751512025-01-012025-12-310001175151ctso:LoanAndSecurityAgreementMember2025-11-132025-11-130001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001175151us-gaap:RetainedEarningsMember2026-01-012026-03-310001175151us-gaap:RetainedEarningsMember2025-01-012025-03-310001175151ctso:ThirdTrancheMember2026-03-310001175151ctso:SecondTrancheMember2026-03-310001175151ctso:FirstTrancheMember2026-03-310001175151srt:MinimumMember2026-03-310001175151srt:MaximumMember2026-03-310001175151ctso:FiniteLivedIntangibleAssetsPatentsIssuedMember2026-03-310001175151ctso:FiniteLivedIntangibleAssetsPatentApplicationsPendingMember2026-03-310001175151ctso:FiniteLivedIntangibleAssetsPatentsIssuedMember2025-12-310001175151ctso:FiniteLivedIntangibleAssetsPatentApplicationsPendingMember2025-12-310001175151us-gaap:EmployeeStockOptionMember2026-03-310001175151us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001175151us-gaap:RestrictedStockUnitsRSUMember2026-03-310001175151ctso:LoanAndSecurityAgreementTrancheTwoaMember2025-11-130001175151us-gaap:CargoAndFreightMember2026-01-012026-03-310001175151us-gaap:CargoAndFreightMember2025-01-012025-03-310001175151ctso:BdistributorMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2026-01-012026-03-310001175151ctso:AdistributorMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-310001175151ctso:AdistributorMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2026-01-012026-03-310001175151ctso:AdistributorMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2025-01-012025-12-310001175151ctso:SeriesRightOfferingMember2025-01-100001175151ctso:SeriesBRightWarrantsMember2025-01-100001175151ctso:SeriesaRightWarrantsMember2025-01-100001175151ctso:WarrantTwoMember2025-11-130001175151ctso:LoanAndSecurityAgreementMember2025-11-130001175151ctso:SeriesaRightWarrantsMember2025-02-240001175151srt:MinimumMemberctso:SeriesBRightWarrantsMember2025-01-100001175151srt:MinimumMemberctso:SeriesaRightWarrantsMember2025-01-100001175151srt:MaximumMemberctso:SeriesBRightWarrantsMember2025-01-100001175151srt:MaximumMemberctso:SeriesaRightWarrantsMember2025-01-100001175151ctso:WarrantOneMember2024-06-280001175151ctso:December132023OfferingMember2023-12-1300011751512025-03-3100011751512024-12-310001175151us-gaap:WarrantMember2026-01-012026-03-310001175151us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001175151us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001175151us-gaap:ConvertibleDebtSecuritiesMember2026-01-012026-03-310001175151ctso:ControlBasedRsusMember2026-01-012026-03-310001175151us-gaap:WarrantMember2025-01-012025-03-310001175151us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001175151us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001175151us-gaap:ConvertibleDebtSecuritiesMember2025-01-012025-03-310001175151ctso:ControlBasedRsusMember2025-01-012025-03-3100011751512026-05-070001175151srt:MinimumMember2026-01-012026-03-310001175151srt:MaximumMember2026-01-012026-03-310001175151srt:MaximumMemberctso:FirstTrancheMember2026-01-012026-03-310001175151us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001175151us-gaap:CommonStockMember2025-01-012025-03-310001175151srt:MinimumMemberctso:LoanAndSecurityAgreementMember2024-06-280001175151srt:MaximumMemberctso:LoanAndSecurityAgreementMember2024-06-280001175151ctso:SeriesaRightWarrantsMember2025-02-242025-02-2400011751512026-03-012026-03-3100011751512025-04-012025-04-300001175151ctso:ThirdTrancheMember2026-01-012026-03-310001175151ctso:SecondTrancheMember2026-01-012026-03-3100011751512025-01-012025-03-3100011751512014-06-012014-06-300001175151ctso:FirstTrancheMember2026-01-012026-03-310001175151srt:MinimumMemberctso:LoanAndSecurityAgreementMember2025-11-130001175151srt:MaximumMemberctso:LoanAndSecurityAgreementMember2025-11-130001175151ctso:LoanAndSecurityAgreementTrancheTwoBMember2025-11-130001175151ctso:LoanAndSecurityAgreementTrancheTwoMember2024-06-280001175151ctso:LoanAndSecurityAgreementTrancheOneMember2024-06-280001175151ctso:LoanAndSecurityAgreementMember2024-06-280001175151ctso:LoanAndSecurityAgreementMember2025-12-310001175151ctso:LoanAndSecurityAgreementMember2026-01-012026-03-310001175151ctso:LoanAndSecurityAgreementTrancheTwoBMember2025-11-132025-11-130001175151ctso:LoanAndSecurityAgreementMember2024-06-282024-06-280001175151ctso:LoanAndSecurityAgreementMember2026-03-3100011751512026-01-012026-03-310001175151ctso:SeriesRightOfferingMember2025-01-102025-01-100001175151ctso:SeriesBRightWarrantsMember2025-06-112025-06-110001175151ctso:SeriesBRightWarrantsMember2025-01-102025-01-100001175151ctso:SeriesaRightWarrantsMember2025-01-102025-01-100001175151ctso:SingleReportableSegmentMember2026-01-012026-03-310001175151ctso:SingleReportableSegmentMember2025-01-012025-03-3100011751512026-03-3100011751512025-12-31iso4217:USDctso:Dxbrli:pureiso4217:USDxbrli:sharesctso:itemxbrli:sharesctso:segment\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**FORM ****10-Q**\n\n**☒**   **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n**For the quarterly period ended****March 31, 2026**\n\n**or**\n\n**☐**   **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n**Commission file number:****001-36792**\n\n**CYTOSORBENTS CORPORATION**\n\n**(Exact name of registrant as specified in its charter)**\n\n​\n\n**Delaware**\n\n  ​ ​ ​\n\n**98-0373793**\n\n**(State or other jurisdiction of**\n\n \n\n**(I.R.S. Employer Identification No.)**\n\n**incorporation or organization)**\n\n \n\n \n\n​\n\n​\n\n​\n\n**305 College Road East******\n\n​\n\n​\n\n**Princeton****,****New Jersey**\n\n​\n\n**08540**\n\n**(Address of principal executive offices)**\n\n​\n\n**(Zip Code)**\n\n​\n\n**(****732****)****329-8885**\n\n**(Registrant’s telephone number, including area code)**\n\n​\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n​\n\nTitle of each class\n\nTrading Symbol(s)\n\nName of each exchange on which registered\n\nCommon Stock, $0.001 par value per share\n\nCTSO\n\nNasdaq Capital Market\n\n​\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑  Yes ☐  No\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n​\n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☑\n\nSmaller reporting company\n\n☑\n\n​\n\n \n\nEmerging growth company\n\n☐\n\n​\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐  Yes ☑  No\n\nAs of May 7, 2026, there were 62,794,748 shares of the issuer’s common stock, $0.001 par value per share (the “Common Stock”), outstanding.\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\nCytoSorbents Corporation\n\nFORM 10-Q\n\nTABLE OF CONTENTS\n\n​\n\n \n\n  ​ ​ ​\n\nPage\n\n[**PART I. FINANCIAL INFORMATION**](#PARTI_383846)\n\n​\n\n​\n\n​\n\n​\n\n[Item 1. Financial Statements](#Item1FinancialStatements_364020)\n\n​\n\n3\n\n \n\n​\n\n \n\n[Condensed Consolidated Balance Sheets as of March 31, 2026 (unaudited) and December 31, 2025](#CONSOLIDATEDBALANCESHEETS_954121)\n\n​\n\n3\n\n[Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2026 and 2025 (unaudited)](#CONSOLIDATEDSTATEMENTSOFOPERATIONS_26607)\n\n​\n\n4\n\n[Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31, 2026 and 2025 (unaudited)](#STOCKHOLDERSEQUITY_422294)\n\n​\n\n5\n\n[Condensed Consolidated Statements of Cash Flows for the three Months Ended March 31, 2026 and 2025 (unaudited)](#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_405660)\n\n​\n\n6\n\n \n\n​\n\n \n\n[Notes to Condensed Consolidated Financial Statements (unaudited)](#NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA)\n\n​\n\n7\n\n \n\n​\n\n \n\n[Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysis_38)\n\n​\n\n23\n\n \n\n​\n\n \n\n[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#Item3QuantitativeandQualitativeDisclosur)\n\n​\n\n29\n\n \n\n​\n\n \n\n[Item 4. Controls and Procedures](#Item4ControlsandProcedures_143501)\n\n​\n\n29\n\n \n\n​\n\n \n\n[**PART II. OTHER INFORMATION**](#PARTII_497852)\n\n​\n\n \n\n​\n\n \n\n[Item 1. Legal Proceedings](#Item1LegalProceedings_599823)\n\n​\n\n32\n\n \n\n​\n\n \n\n[Item 1A. Risk Factors](#Item1ARiskFactors_310556)\n\n​\n\n32\n\n \n\n​\n\n \n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#Item2UnregisteredSalesofEquity_828932)\n\n​\n\n32\n\n \n\n​\n\n \n\n[Item 3. Defaults Upon Senior Securities](#Item3DefaultsUponSeniorSecurities_642777)\n\n​\n\n32\n\n \n\n​\n\n \n\n[Item 4. Mine Safety Disclosures](#Item4MineSafetyDisclosures_898507)\n\n​\n\n32\n\n \n\n​\n\n \n\n[Item 5. Other Information](#Item5OtherInformation_810334)\n\n​\n\n32\n\n \n\n​\n\n \n\n[Item 6. Exhibits](#Item6Exhibits_572929)\n\n​\n\n33\n\n​\n\n​\n\n​\n\n[Signatures](#SIGNATURES_469209)\n\n​\n\n34\n\n​\n\nThis Report includes our trademarks and trade names, such as “CytoSorb,” “CytoSorb XL,” “ECOS-300CY,” “BetaSorb,” “ContrastSorb,” “DrugSorb,” “DrugSorb-ATR,” “HemoDefend-RBC,” “HemoDefend-BGA,” “K+ontrol,” “VetResQ,” “PuriFi,” and “HotSwap,” which are protected under applicable intellectual property laws and are the property of CytoSorbents Corporation and its subsidiaries. This Report also contains the trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Report may appear without the ™, ®, or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by these other parties.\n\n​\n\n​\n\n2\n\n[Table of Contents](#TOC)\n\nPART I — FINANCIAL INFORMATION"}